Kuros Biosciences AG/  CH0325814116  /

After the merger with Cytos Biotechnology Ltd in 2016 the Kuros Biosciences Ltd is developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off of the Eidgenössische Technische Hochschule Zürich (ETHZ), Kuros has developed a pipeline of products based upon its proprietary technology platforms. These platforms were developed from work carried out at ETHZ, at the University of Zürich and at the California Institute of Technology (CalTech). In addition, in early 2017 Kuros acquired Xpand Biotechnology to gain access to its MagnetOs family of bone graft substitutes and the associated surface science technology. Kuros has attractive commercial prospects in key market segments as well as an EU hub for future clinical and distribution operations. In June 2017 Kuros Biosciences has received CE certification for its novel dural sealant, Neuroseal®. The CE certification allows for the commercialization of the product anywhere in the European Economic Area. MagnetOs is approved for sale in the EU for orthopedic, spine and dental applications, and in the US for posterolateral spinal fusion. In addition, MagnetOs Putty is approved for sale as an autograft extender in posterolateral spine in US. Kuros Biosciences Ltd is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands.